C12N 2501/515
Cd3, t-cell receptor complex
Official title: CD3, T-cell receptor complex
C12N2501/515 (Cd3, t-cell receptor complex) appears on 508 US grants and 1,222 published applications in this corpus.
Search patents in C12N- Granted patents
- 508
- Published applications
- 1,222
- Assignees
- 529
- Inventors
- 2,242
- Latest grant
- 11 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 2 | 0 |
| 1995 | 1 | 0 |
| 1996 | 1 | 0 |
| 1997 | 2 | 0 |
| 1998 | 4 | 0 |
| 1999 | 2 | 0 |
| 2000 | 4 | 0 |
| 2001 | 2 | 5 |
| 2002 | 5 | 15 |
| 2003 | 4 | 22 |
| 2004 | 5 | 19 |
| 2005 | 8 | 11 |
| 2006 | 3 | 12 |
| 2007 | 2 | 7 |
| 2008 | 2 | 8 |
| 2009 | 7 | 15 |
| 2010 | 11 | 24 |
| 2011 | 14 | 21 |
| 2012 | 8 | 26 |
| 2013 | 7 | 23 |
| 2014 | 19 | 21 |
| 2015 | 24 | 26 |
| 2016 | 18 | 28 |
| 2017 | 16 | 39 |
| 2018 | 19 | 54 |
| 2019 | 24 | 62 |
| 2020 | 26 | 80 |
| 2021 | 34 | 112 |
| 2022 | 40 | 135 |
| 2023 | 32 | 137 |
| 2024 | 53 | 135 |
| 2025 | 68 | 112 |
| 2026 | 39 | 73 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Process for producing donor-batched cells expressing a recombinant receptor11 Aug 2026US 12,703,733 B2Juno Therapeutics, Inc.
- Manufacturing process for making t cells expressing chimeric antigen receptors4 Aug 2026US 12,698,317 B2Crispr Therapeutics AG
- Methods for engineering allogeneic and highly active T cell for immunotheraphy14 Jul 2026US 12,680,076 B2Cellectis
- Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion7 Jul 2026US 12,673,982 B2Iovance Biotherapeutics, Inc.
- Method for expansion of double negative regulatory T cells30 Jun 2026US 12,668,778 B2University Health Network
- Metabolically enhanced vd1 t cells and uses thereof8 Oct 2026US 2026/0308518 A1
- Methods of enhancing or modifying nk cells8 Oct 2026US 2026/0308525 A1Zelluna Immunotherapy AS
- Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy1 Oct 2026US 2026/0293881 A1Iovance Biotherapeutics, Inc.
- Treatment of autoimmune disorders using chimeric antigen receptor therapy1 Oct 2026US 2026/0295043 A1Novartis AG
- Method for culturing cord blood-derived natural killer cells using transformed t-cells1 Oct 2026US 2026/0297526 A1GC Cell Corporation
Most cited
By later US patents
- Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells512US 6,352,694 B1Genetics Institute, Inc. · 2002
- Methods for selectively stimulating proliferation of T cells452US 6,534,055 B1Genetics Institute, Inc. · 2003
- Simultaneous stimulation and concentration of cells422US 6,797,514 B2XCYTE Therapies, Inc. · 2004
- Simultaneous stimulation and concentration of cells398US 6,867,041 B2XCYTE Therapies, Inc. · 2005
- Methods of treating HIV infected subjects386US 6,905,680 B2Genetics Institute, Inc. · 2005